DAFNA Capital Management LLC cut its position in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) by 85.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 87,989 shares of the company's stock after selling 514,905 shares during the quarter. DAFNA Capital Management LLC owned approximately 0.09% of Acelyrin worth $276,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new stake in shares of Acelyrin in the fourth quarter valued at approximately $33,000. 4WEALTH Advisors Inc. bought a new stake in Acelyrin during the 4th quarter valued at $35,000. Hsbc Holdings PLC bought a new stake in Acelyrin during the 4th quarter valued at $36,000. RPO LLC bought a new stake in Acelyrin during the 4th quarter valued at $46,000. Finally, Virtu Financial LLC bought a new position in Acelyrin in the 3rd quarter worth $50,000. 87.31% of the stock is currently owned by hedge funds and other institutional investors.
Insider Transactions at Acelyrin
In related news, CEO Mina Kim sold 17,986 shares of Acelyrin stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now owns 671,753 shares in the company, valued at approximately $1,840,603.22. The trade was a 2.61% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 13.60% of the company's stock.
Acelyrin Stock Performance
Shares of Acelyrin stock traded down $0.24 during trading on Tuesday, hitting $2.24. The company's stock had a trading volume of 1,160,937 shares, compared to its average volume of 1,200,997. The company has a fifty day simple moving average of $2.45 and a two-hundred day simple moving average of $3.07. The company has a market capitalization of $226.03 million, a PE ratio of -0.91 and a beta of 1.07. Acelyrin, Inc. has a 52 week low of $1.85 and a 52 week high of $7.25.
Acelyrin (NASDAQ:SLRN - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.07. As a group, analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current year.
Acelyrin Profile
(
Free Report)
Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Recommended Stories
Before you consider Acelyrin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acelyrin wasn't on the list.
While Acelyrin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
